Key Stats for DexCom Stock
- Price change for DexCom stock: 7%
- $DXCM Share Price as of May. 15: $62
- 52-Week High: $90
- $DXCM Stock Price Target: $83
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
DexCom (DXCM) stock surged almost 7% on Friday, and there was a lot happening all at once.
The biggest headline: activist investor Elliott Investment Management took a major stake in DexCom and reached a cooperation agreement with the board. Two new independent directors will be added as part of the deal.
Elliott’s Marc Steinberg didn’t mince words, calling DexCom “one of the most compelling earnings growth profiles in MedTech.”
The news dropped on the same day as DexCom’s 2026 Investor Day in Mesa, Arizona. The company laid out an ambitious plan to grow beyond diabetes devices and become a broader biosensing company.
Management also announced a new $1 billion share buyback program — replacing an older one with just $250 million left — and committed to using at least 50% of free cash flow each year on repurchases.
The long-range targets through 2030 gave investors plenty to get excited about.
- DexCom is targeting a non-GAAP gross margin of 67% to 69%,
- An operating margin of 29% to 30%, and
- An adjusted EBITDA margin of 36% to 37%.
- The company’s next-generation G8 product is also expected to launch in roughly 18 months.
Wall Street piled on with support.
- Piper Sandler reiterated a Buy with a $75 price target.
- Truist Securities maintained its Buy rating and set a $80 target, saying the 2030 plan looks not just achievable but potentially beatable.
See analysts’ growth forecasts and price targets for DexCom stock (It’s free) >>>
What the Market Is Telling Us About DexCom Stock
What makes the DexCom stock move even more impressive is the backdrop. The Dow fell, the S&P 500 dropped, and the Nasdaq slid on the same day. Rising Treasury yields and geopolitical worries were weighing on the broader market.
DexCom stock moving sharply higher while everything else was selling off says a lot. This wasn’t a rising tide lifting all boats — it was company-specific news doing the heavy lifting.
With Elliott now involved, a clear profitability roadmap, and a new product on the horizon, DexCom stock has multiple reasons for investors to pay close attention.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does DexCom Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
